U.K. Health Agency To Review Advertising Materials For All New Medicines
This article was originally published in The Pink Sheet Daily
MHRA expects a review period that will take between three and six months.
You may also be interested in...
Independent review panel will be established to handle complaints about pharmaceutical advertising.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.